Plaque Psoriasis

This analysis suggests that GLP-1 RAs provide promise for those with HS and obesity and potentially for such individuals without obesity via immunological impacts.

The G-EPOSS study demonstrated the long-term impacts of guselkumab on patients’ psoriasis symptoms, sexual impairment, and perceived stigmatization.

Findings highlight an association between psoriasis and risks of all-cause, cardiovascular, infection-related, and suicide mortality.

Recent interview- and survey-based research has quantified the extent to which GPP impacts patients, examining both symptoms and mental health outcomes.

This systematic review and meta-analysis found that biologic switching was shown to be safe and effective among patients with psoriasis.

This summary of dermatology news coverage from the month of August 2025 highlights some of the most notable stories in this medical subfield.

These data from the ICONIC-LEAD study were presented at DERM 2025, highlighting the efficacy and safety of icotrokinra in patients with psoriasis.

News coverage from DERM 2025 in the field of psoriasis is highlighted in this post-conference summary.

This case–control study compared sleep quality, risk of obstructive sleep apnoea, and quality of life between those with psoriasis and healthy controls.

The announcement of this NDA submission to the FDA highlights icotrokinra, a first-in-class investigational targeted oral peptide for plaque psoriasis.

This systematic review evaluated current research on dual biologic treatments in patients living with inflammatory skin conditions.

These data resulted from a sub-study of the open-label extension (OLE) of the randomized, placebo-controlled phase 3 ‘Balance’ analysis.

In this video, the third in a 6-part series, panelists discuss recent advancements in PsO management.

In this video, the second in a 6-part series, panelists discuss recent advancements in PsO management.

In this video, the first in a 6-part series, panelists discuss recent advancements in PsO management.

Findings highlight the ongoing burden of generalized pustular psoriasis and suggest patients may benefit from targeted biologic therapies like the FDA-approved spesolimab.

In ARRECTOR, patients reported symptom relief and improved quality of life as early as week 2, with strong tolerability and safety through week 8.

Based on reduced FOXP3+ expression in patients, investigators have drawn a strong correlation between MetS due to psoriasis and immune dysregulation.

Findings suggest pediatric patients with guttate or inverse psoriasis may warrant evaluation for pharyngeal or anogenital bacterial infections.

Overall, older treatment strategies such as methotrexate and phototherapy still led the way for cost-effectiveness.

This FDA news recap highlights some of the most notable approvals and actions by the organization in dermatology during Q2 2025.

In our recap for Q2 in dermatology, we spotlight clinical trial findings, recent updates, and advancements in different disease states.

In the BE BRIGHT trial presented at SDPA 2025, patients receiving continuous bimekizumab therapy maintained high PASI 90 and PASI 100 response rates over 5 years.

At SDPA 2025, Gordon presented on the future of dermatology, discussing current drugs being evaluated for atopic dermatitis, psoriasis, and hidradenitis suppurativa.